Cipla Ltd.
Mumbai Central
Mumbai 400 008

12th February 2014

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

**Scrip Code: 500087**

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

**Scrip Code: CIPLA EQ**

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxemberg

Dear Sirs,

Please find enclosed copy of press release dated 12th February, 2014 in relation to appointment of Dr. Peter Mugyenyi as an Independent Director of the Company.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Encl: as above

Phone : (9122) 23082891, 23095521 • Fax : (9122) 23070013, 23070393, 23070385

**PRESS RELEASE**

# Cipla appoints Dr. Peter Mugyenyi as an Independent Director on the Board

**India, Mumbai, 12th February, 2014:** Cipla, a global pharmaceutical company is delighted to announce the appointment of Dr. Peter Mugyenyi as an independent director on the Board with immediate effect. Dr. Mugyenyi is the Director and Co-Founder of the Joint Clinical Research Centre (JCRC) based in Kampala. He is highly regarded globally for his leadership in helping Africa battle its mounting AIDS epidemic. A pediatrician by training, Dr. Peter Mugyenyi is recognized as one of the worlds' foremost specialists and researchers in the field of HIV/AIDS.

Announcing the appointment, **Dr. Y K Hamied, Chairman, Cipla Limited** said: "It is a privilege for Cipla to have Dr. Mugyenyi as a member of Cipla's board of directors. His presence would be most influential in the heart of the highest governing body of Cipla. I believe that as a world leader, Dr. Mugyenyi will be a source of inspiration for us, someone who can also guide us in our journey towards our vision of 'None shall be denied'."

**Dr. Peter Mugyenyi said:** "I am proud to be part of Cipla's contribution to humanity and would like to emphasize that innovation in the crucial area of human survival should not be entirely dependent on revenue generation. It should primarily aim at alleviating the human suffering and saving lives. This does not contradict fair trade, because business success and humanism are not incompatible." He also added, "Establishing the earnest partnership between doctors and the pharmaceutical drug industry would help make critical life-saving drugs accessible to all in need."

Dr. Peter Mugyenyi is the author of *Genocide by Denial: How Profiteering from HIV/AIDS Killed Millions.* Published in 2008, a book that details the story of how Western Governments and drug companies callously oversaw the death of millions of Africans who were unable to afford their branded drugs. A follow-up of this book was published in 2013. Dr. Mugyenyi played a major consultative role in the formulation of the PEPFAR (President's Emergency Plan for AIDS relief) program, which was announced in the 2003 State of the Union address by President George W. Bush. PEPFAR has since put millions of Africans on lifesaving anti-retroviral treatment.

## About Cipla

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla's turnover in 2012-13 was 1.5 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard of quality both domestically and internationally.

**Media Contact:**

Charlotte Chunawala
Corporate Communications
Mob: +91 7506257377
Email: charlotte.chunawala@cipla.com

Jaisingh Balakrishnan
Corporate Communications
Mob: +91 9833836185
Email: jaisingh.krishnan@cipla.com